1972
Clinical trials with 5-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4-carboxamide (NSC-82196) given intravenously.
Bagley C, Canellos G, Young R, Gallelli J, Devita V. Clinical trials with 5-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4-carboxamide (NSC-82196) given intravenously. Cancer Chemotherapy Reports 1972, 56: 387-91. PMID: 19051499.Peer-Reviewed Original ResearchConceptsClinical trialsDose-limiting toxic effectPhase II trialBone marrow toxicityConsecutive daily injectionsTime of onsetDegree of severitySevere nauseaII trialObjective responseDaily injectionsMarrow toxicityPatientsTrialsToxic effectsToxicityNauseaVomitingPainLymphomaMelanomaTumorsLymphosarcomaAdministrationDose
1970
Combination chemotherapy with nitrogen mustard, vincristine, procarbazine, and prednisone in lymphosarcoma and reticulum cell sarcoma
Lowenbraun S, DeVita V, Serpick A. Combination chemotherapy with nitrogen mustard, vincristine, procarbazine, and prednisone in lymphosarcoma and reticulum cell sarcoma. Cancer 1970, 25: 1018-1025. PMID: 4910254, DOI: 10.1002/1097-0142(197005)25:5<1018::aid-cncr2820250505>3.0.co;2-a.Peer-Reviewed Original ResearchConceptsReticulum cell sarcomaComplete remissionPartial remissionRCS patientsCell sarcomaLSA patientsUnmaintained complete remissionOnset of therapyCombination of agentsGeneralized lymphosarcomaModerate myelosuppressionCombination chemotherapyRC patientsTherapy completionMean durationPatientsRemissionLymphosarcomaSarcomaVincristineDiseaseNitrogen mustardSurvivalSubstantial durationDuration